Viscosupplementation: Managed care issues for osteoarthritis of the knee

Journal of Managed Care Pharmacy

Volumn 13, Issue 4 SUPPL., 2007, Pages

  Arnold, William ^a   Fullerton, Dwight S ^b   Holder, Sharon ^c   May, Coral S ^d  

^a ILLINOIS BONE AND JOINT INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Oschner Health Center   (United States)

^d e3 Communication   (United States)

Author keywords

Cartilage degrading mechanisms; Cost effectiveness; Haluronate; Hyaluronan; Hylan; Managed care; Osteoarthritis; Viscosupplementation

Indexed keywords

ANALGESIC AGENT; ANTICOAGULANT AGENT; CAPSAICIN; CELECOXIB; CHOLINE MAGNESIUM TRISALICYLATE; CHONDROITIN SULFATE; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DEXTROPROPOXYPHENE; EUFLEXXA; GLUCOCORTICOID; GLUCOSAMINE; GLYCOSAMINOGLYCAN; HYALURONIC ACID; HYALURONIC ACID DERIVATIVE; IBUPROFEN; LIDOCAINE; MISOPROSTOL; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; PLACEBO; PREDNISOLONE; PROTON PUMP INHIBITOR; ROFECOXIB; TRAMADOL; TRIAMCINOLONE HEXACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ADJUVANT THERAPY; AGING; ANALGESIA; ANTIOXIDANT ACTIVITY; ARTHRALGIA; ARTHROCENTESIS; ARTICLE; BRACE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSERVATIVE TREATMENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISABILITY; DRUG COST; DRUG DEPENDENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERANCE; ESTROGEN THERAPY; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENETIC PREDISPOSITION; GOUT; HEART INFARCTION; HEAT; HUMAN; HYPERPARATHYROIDISM; HYPOTHYROIDISM; IMMUNOMODULATION; INJECTION SITE ERYTHEMA; JOINT EFFUSION; JOINT RADIOGRAPHY; KINESIOTHERAPY; KNEE INJURY; KNEE OSTEOARTHRITIS; KNEE PAIN; LIVER FAILURE; LIVER TOXICITY; LOW DRUG DOSE; MANAGED CARE; META ANALYSIS; MONOTHERAPY; MUSCLE ATROPHY; MUSCLE WEAKNESS; NEPHROTOXICITY; NOCICEPTION; OBESITY; OPTIMAL DRUG DOSE; PAIN; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PATIENT EDUCATION; PATIENT SATISFACTION; POSTMENOPAUSE; PREVALENCE; PROTECTIVE CLOTHING; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; STOMACH DISEASE; STRESS; STROKE; SWELLING; SYSTEMATIC REVIEW; TENDON RUPTURE; TOTAL KNEE REPLACEMENT; VASCULITIS; WEIGHT REDUCTION;

ADULT; DISEASE PROGRESSION; HEALTH CARE COSTS; HUMANS; HYALURONIC ACID; MANAGED CARE PROGRAMS; NORTH AMERICA; OSTEOARTHRITIS, KNEE; PATIENT SELECTION; VISCOSUPPLEMENTATION; VISCOSUPPLEMENTS;

EID: 34250814563     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.s4.3     Document Type: Article

References (85)

1. Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwits M, eds. Osteoarthritis. The Merck Manual of Diagnosis and Therapy. 18th ed. Whitehouse Station. NJ: Merck Research Laboratories; 2006:294-97.
2. Creamer P, Lethbridge-Cejku M, Hochberg MC. Factors associated with functional impairment in symptomatic knee osteoarthritis. Rheumatology (Oxford). 2000;39:490-96.
3. Gabriel SE, Crowson CS, O'Fallon WM. Costs of osteoarthritis: estimates from a geographically defined population. J Rheumatol. 1995;22(suppl 43):23-25.
4. Lanes SF, Lanza LL, Radensky PW, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting. Arthritis Rheum. 1997;40:1475-81.
5. Mandelbaum B, Waddell D. Etiology and pathophysiology of osteoarthritis. Orthopedics. 2005;28(suppl):S207-S214.
6. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004;140:441-51.
7. Moskowitz RW, Kelly MA, Lewallen DG. Understanding osteoarthritis of the knee - causes and effects. Am J Orthop. February 2004;33(2 suppl):5-9.
8. Kaiyama J, Uzuki M. Alteration of hyaluronic acid property in synovial fluid of patient with osteoarthritis. J Iwate Med Assoc. 2006;58:9-21.
9. Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-94. J Rheumatol. 2006; 33:2271-79.
10. American Academy of Orthopaedic Surgeons. The impact of osteoarthritis of the knee. April 2003. Available at: http://www.orthoinfo.org/fact/ printer_page.cfm?topcategory=knee&Thread_ID=419. Accessed December 17, 2006.
11. American Academy of Orthopaedic Surgeons. Osteoarthritis of the knee: state of the condition. Osteoarthritis of the Knee: A Compendium of Evidence-based Information and Resources. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2004. Available at: http://www.aaos.org/ Research/documents/OAinfo_knee_state.pdf. Accessed December 25, 2006.
12. Fan Z, Tardif G, Boileau C, et al. Identification in human osteoarthritic chondrocytes of proteins binding to the novel regulatory site AGRE in the human matrix metalloprotease 13 proximal promoter. Arthritis Rheum. 2006;54:2471-80.
13. Jinks C, Jordan K, Croft P. Disabling knee pain - another consequence of obesity: results from a prospective cohort study. BMC Public Health. 2006;6:258.
14. Zhang Y, Xu L, Nevitt MC, et al. Comparison of the prevalence of knee osteoarthritis between the elderly Chinese population in Beijing and Whites in the United States: the Beijing osteoarthritis study. Arthritis Rheum. 2001;44:2065-71.
15. Felson DT, Naimark A, Anderson J, et al. The prevalence of knee osteoarthritis in the elderly: the Framingham Osteoarthritis Study. Arthritis Rheum. 1987;30:914-18.
16. Lawrence RC, Hochberg MC, Kelsey JL, et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol. 1989;16:427-41.
17. Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133:635-46.
18. Oliveria SA, Felson DT, Klein RA, Reed JI, Walker AM. Estrogen replacement therapy and the development of osteoarthritis. Epidemiology. 1996;7:415-19.
19. Sowers MF. Epidemiology of risk factors for osteoarthritis: systemic factors. Curr Opin Rheumatol. 2001;13:447-51.
20. Holmberg S, Thelin A, Thelin N. Is there an increased risk of knee osteoarthritis among farmers? A population-based case-control study. Int Arch Occup Environ Health. 2004;77:345-50.
21. Thelin N, Holmberg S, Thelin A. Knee injuries account for the sports-related increased risk of knee osteoarthritis. Scand J Med Sci Sports. 2006;16:329-33.
22. Cooper C, Dennison C. Osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, eds. Osteoarthritis. Oxford, NY: Oxford University Press; 1998:237-49.
23. Hannan MT, Felson DT, Pincus T. Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. J Rheumatol. 2000;27(6):1513-17.
24. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29:1039-49.
25. Snibbe JC, Gambardella RA. Treatment options for osteoarthritis. Orthopedics. 2005;28(suppl):S215-S220.
26. American College of Rheumatology Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000;43:1905-15.
27. Petrella RJ, DiSilvestro MD, Hildebrand C. Effects of hyaluronate sodium on pain and physical functioning in osteoarthritis of the knee. Arch Intern Med. 2002;162:292-98.
28. McClean G. The analgesic efficacy of topical capsaicin is enhanced by glyceryl trinitrate in painful osteoarthritis: a randomized, double-blind, placebo controlled study. Eur J Pain. 2000;4(4):355-60.
29. Gammaitoni AR, Galer BS, Onawola R, Jensen MP, Argoff CE. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale. Curr Med Res Opin. 2005;20(suppl 2):513-S19.
30. Burch F, Codding C, Patel N, Sheldon E. Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial. Osteoarthritis Cartilage. 2004;12(3):252-55.
31. Towheed TE, Maxwell L, Judd MG, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006;25(1):CD004257.
32. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: a meta-analysis of randomized controlled trials. Ann Rheum Dis. 2004;63:901-07.
33. Wolfe F, Zhao S, Lane N. Preference for nonsteroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum. 2000;43:378-85.
34. Pincus T, Swearingen C, Cummins P, Callahan LF. Preference for nonsteroidal anti-inflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteo arthritis. J Rheumatol. 2000; 27:1020-27.
35. Bond GR, Hite LK. Population-based incidence and outcome of acetaminophen poisoning by type of ingestion. Acad Emerg Med. 1999;6(11): 1115-120.
36. Larson A, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42:1364-72.
37. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily. JAMA. 2006;296:87-93.
38. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998;279: 657-62.
39. Temple AR, Benson GD, Zinsenheim JR, Schweinle JE. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis. Clin Ther. 2006;28:222-35.
40. Bjordal JM, Ljunggren AE, Klovning A, Slordal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomized placebo controlled trials. BMJ. 2004;329:1317-22.
41. Buffum M, Buffum JC. Nonsteroidal anti-inflammatory drugs in the elderly. Pain Manag Nurs. 2000;1:40-50.
42. Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee. JAMA. 2002;287:64-71.
43. Hawkey CJ, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum. 2000;43:370-77.
44. U.S. Food and Drug Administration. COX-2 Selective (includes Bextra, Celebrex, and Vioxx) and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) April 6, 2005. Available at: http://www.fda.gov/cder/drug/ infopage/COX2/default.htm#COX2. Accessed December 17, 2006.
45. Dalgin P, TPS-OA Study Group. Comparison of tramadol and ibuprofen for the chronic pain of osteoarthritis [abstract]. Arthritis Rheum. 1997;40(suppl 9): 586.
46. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354:795-808.
47. Bellamy N, Campbell J, Robinson V, et al. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;(2): CD005328.
48. Schumacher HR, Chen LX. Injectable corticosteroids in treatment of arthritis of the knee. Am J Med. 2005;118:1208-14.
49. Kurtz S, Mowat F, Ong K, et al. Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002. J Bone Joint Surg. 2005;87:1487-97.
50. Waddell DD, Cefalu CA, Bricker DC. A second course of hylan G-F 20 for the treatment of osteoarthritic knee pain: 12-month patient follow-up. J Knee Surg. 2005;18:7-15.
51. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Visco-supplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;(2):CD005321.
52. Bagga H, Burkhardt D, Sambrook P, March L. Longterm effects of intraarcicular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol. 2006;33:946-50.
53. Marshall KW. Viscosupplementation for osteoarthritis: current status, unresolved issues and future directions. J Rheumatol. 1998;25:2056-58.
54. Euflexxa [prescribing information]. Suffern, NY: Ferring Pharmaceuticals, Inc.; 2006.
55. Synvisc [prescribing information]. Ridgefield, NJ: Genzyme Corp.; 2004.
56. Orthovisc [prescribing information]. Woburn, MA: Anika Therapeutics, Inc.; 2005.
57. Hyalgan [prescribing information]. New York, NY: Sanofi-Synthelabo Inc.; 2001.
58. Supartz [prescribing information]. Tokyo, Japan: Seikagaku Corp.; 2006.
59. Wobig M, Bach G, Beks P, et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther. 1999;21:1549-62.
60. Wang CT, Lin J, Chang CJ, Lin YT, Hou SM. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee: a meta-analysis of randomized controlled trials. J Bone Joint Surg Am. 2004;86-A:538-45.
61. Pozo MA, Balazs EA, Belmonte C. Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative. Exp Brain Res. 1997;116:3-9.
62. Gomis A, Pawlak M, Balazs EA, Schmidt RF, Belmonte C. Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthritis Rheum. 2004;50:314-26.
63. Sato H, Takahaski T, Ide H, et al. Antioxidant activity of synovial fluid, hyaluronic acid, and two subcomponents of hyaluronic acid. Synovial fluid scavenging effect is enhanced in rheumatoid arthritis patients. Arthritis Rheum. 1988;31:63-71.
64. Forrester JV, Balazs EA. Inhibition of phagocytosis by high molecular weight hyaluronate. Immunology. 1980;40:435-46.
65. Tobetto K, Nakai K, Akatsuka M, Yasui T, Ando T, Hirano S. Inhibitory effects of hyaluronan on neutrophil-mediated cartilage degradation. Connect Tissue Res. 1993;29:181-90.
66. Evanich JD, Evanich CJ, Wright MB, Rydlewicz JA. Efficacy of intra-articular hyaluronic acid injections in knee osteoarthritis. Clin Orthop Relat Res. 2001;(390):173-81.
67. Vad VB, Bhat AL, Sculco TP, Wickiewicz TL. Management of knee osteoarthritis: knee lavage combined with hylan versus hylan alone. Arch Phys Rehabil. 2003;84:634-37.
68. Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized chemical trial. Hyalgan Study Group. J Rheumatol. 1998;25:2203-12.
69. Kirwan JR, Rankin E. Intra-articular therapy in osteoarthritis. Baillieres Clin Rheumatol. 1997;11:769-94.
70. Kemper F, Gebhardt U, Meng T, Murray C. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005;21:1261-1269.
71. Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Medicis R. Vizscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol. 1996;23:1579-85.
72. American Academy of Orthopaedic Surgeons. Viscosupplementation treatment for osteoarthritis. November 2000. Available at: http://www.orthoinfo.org/fact/thr_report.cfm?Thread_ID= 245&topcategory=Arthritis. Accessed December 25, 2006.
73. Raman R, Dutta A, Day N, Shaw CJ, Johnson GV. The efficacy of hylan G-F 20 and sodium hyaluronate in the treatment of osteoarthritis of the knee: a prospective randomized double-blinded clinical trial. Osteoarthritis Cartilage. 2006;14(suppl B):S162.
74. Lohmander LS, Dalen N, Englund G, et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomized, double-blind, placebo controlled multicentre trial. Ann Rheum Dis. 1996;55:424-31.
75. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998;20:410-23.
76. Pagnano M, Westrich G. Successful nonoperative management of chronic osteoarthritis pain of the knee: safety and efficacy of retreatment with intra-articular hyaluronans. Osteoarthritis Cartilage. 2005;13:751-61.
77. Karatosun V, Unver B, Gocen Z, Sen A, Gunal I. Intra-articular hyaluronic acid compared with progressive knee exercises in osteoarthritis of the knee: a prospective randomized trial with long-term follow-up. Rheumatol Int. 2006;26:277-84.
78. Marshall KW. European Federation of National Associations of Orthopedics and Traumatology Brussels Congress. June 1999, Abstracts. J Bone Joint Surg Br. 1999;81(suppl 2):S123-S269.
79. Bell M. 4th World Congress of the Osteoarthritis Research Society International (OARSI). Vienna, Austria, September 16-19, 1999. Abstracts. Osteoarthritis Cartilage. 1999;7(suppl A):S1-S38.
80. Waddell DD, Bricker DC. Total knee replacement delayed during six years of hylan G-F 20 use in orthopedic practice. J Manag Care Pharm. 2007;13(2):113-21. Available at: http://www.amcp.org/data/jmcp/p113-21/ pdf. Accessed April 23, 2007.
81. Hamburger MI, Lakhanpal S, Mooar PA, Oster D. Intra-articular hyaluronans: a review of product-specific safety profiles. Semin Arthritis Rheum. 2003;32(5):296-309.
82. Torrance GW, Raynauld JP, Walker V, et al.; Canadian Knee OA Study Group. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 2 of 2): economic results. Osteoarthritis Cartilage. 2002;10:518-27.
83. Waddell D, Rein A, Panarites C, Coleman PM, Weiss C. Cost implications of introducing an alternative treatment for patients with osteoarthritis of the knee in a managed care setting. Am J Manag Care. 2001;7:981-91.
84. Baker CL, Ferguson CM. Future treatment of osteoarthritis. Orthopedics. 2005;28(2 suppl):S227-S234.
85. Kelly MA, Moskowitz RW, Lieberman JR. Hyaluronan therapy: looking toward the future. Am J Orthop. 2004;33(2 suppl):23-28.